← Leaderboards
Timothy Patrick Sheahan
Rockefeller University
$10,595,033
Attributed
$14,304,625
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.7M · FY2009–22$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$14,304,625 · 4
By mechanism
R01$7,030,435 · 1
U19$6,734,714 · 1
R21$388,750 · 1
F32$150,726 · 1
Top collaborators
- Ralph S Baric7 shared
- Amy C Sims3 shared
Most similar at Rockefeller University
Same institution · by research overlap
- Charles M. Rice$80,497,748
- Cynthia L De La Fuente$148,182
- Daniel A Calarese$148,182
- Marina Caskey$39,777,285
- Meike Dittmann$3,056,621
Others in their field
Top investigators on “Virus Replication”
- Constance Ann Benson · University Of California, San Diego$187,673,896
- Judith S. Currier · University Of California Los Angeles$137,892,773
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Barton F Haynes · Duke University$110,672,613
- Charles M. Rice · Rockefeller University$53,754,576
- Rama Rao Amara · Emory University$53,347,944
Research focus
Virus ReplicationCellsAntiviral AgentsImmuneInfectionPathway InteractionsVirusProteinsDesignProgramsAntiviral TherapyMiddle East Respiratory Syndrome CoronavirusPathogenesisIn VivoCell Culture TechniquesLungPublic HealthIn VitroCoronavirus InfectionsFutureCoronavirusPathogenicityFamilyEpithelial Cells
Grant awards (14)
Developing Broad-Spectrum Antivirals Targeting Coronavirus Replicase and Helicase$6,734,714
U19 · FY2022 · AI · contact PI
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV$1,166,670
R01 · FY2021 · AI
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV$1,166,670
R01 · FY2020 · AI
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV$458,053
R01 · FY2020 · AI
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV$450,462
R01 · FY2020 · AI
How MERS-CoV Regulates Immunity in Human Lung Tissue$166,889
R21 · FY2020 · AI
How MERS-CoV Regulates Innate Immunity in Primary Human Lung Cells$27,486
R21 · FY2020 · AI · contact PI
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV$1,166,670
R01 · FY2019 · AI
How MERS-CoV Regulates Innate Immunity in Primary Human Lung Cells$194,375
R21 · FY2019 · AI · contact PI
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV$1,166,670
R01 · FY2018 · AI
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV$1,455,240
R01 · FY2017 · AI
Hepatitis C virus host interactions in micropatterened hepatocyte co-cultures$53,042
F32 · FY2011 · AI · contact PI
Hepatitis C virus host interactions in micropatterened hepatocyte co-cultures$50,474
F32 · FY2010 · AI · contact PI
Hepatitis C virus host interactions in micropatterened hepatocyte co-cultures$47,210
F32 · FY2009 · AI · contact PI